The adaptor protein Crk in immune responses

免疫反应中的接头蛋白 Crk

基本信息

  • 批准号:
    9428868
  • 负责人:
  • 金额:
    $ 53.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-03-09 至 2018-02-12
  • 项目状态:
    已结题

项目摘要

Project Summary Natural killer (NK) cells play an important role in the human immune response to infection and malignancy. How these cells effectively distinguish between diseased and healthy tissue is one of the key unsolved problems in immunology today. The proposed work seeks to identify the mechanism(s) by which the small adaptor protein CT10 regulator of kinase (Crk), and its phosphorylation, control NK cell activation and inhibition by using both human NK cells and novel NK cell-specific conditional knockout mice. The long-term goal is to use this knowledge and the novel imaging techniques developed herein to uncover the molecular basis of NK cell activation and inhibition, and to develop new treatments for human primary immunodeficiency diseases and chronic diseases such as cancer and viral infection. NK cells kill target cells through the polarized release of lytic granules through a specialized region of cell-cell contact known as the immunological synapse (IS). Through previous studies of the cytotoxic (Liu, D. et al., Immunity, 2009, Cover Article) and inhibitory (Liu, D. et al., Immunity, 2012) IS, we discovered that Crk plays an essential upstream role at the IS, influencing signaling events required for both activation and inhibition. The molecular mechanisms underlying this dual role, however, remain unclear. We hypothesize that receptor-driven phosphorylation of Crk acts as a molecular switch, driving a conformational change, which in turn determines Crk's ability to interact with critical downstream signaling molecules and ultimately shapes the actin cytoskeleton into a functional IS. Guided by strong preliminary data, we will test these hypotheses via three Specific Aims: 1) Define the precise molecular mechanisms by which Crk controls NK cell activation and inhibition. The proposed work capitalizes on the recent explosion in single molecule imaging and will bring cutting-edge single molecule imaging technology to the field of NK research, with a focus on human primary immunodeficiency diseases; 2) Determine the role of Crk-like protein (CrkL) in NK cells from patients with partial DiGeorge syndrome (pDGS). Using one of most common (1 in 4,000 births) immunodeficiency diseases, pDGS (mainly caused by CrkL haploinsufficiency), we will determine how loss of CrkL function affects NK cell-mediated cytotoxicity in pDGS and its molecular mechanisms; 3) Determine whether Crk is required for NK function in vivo. Leveraging novel NK cell-specific Crk knockout mice that we have already generated, we will determine the roles that Crk molecules play in NK cell-mediated immune responses to viral infection and cancer in vivo. The proposed work involves key signaling players and novel regulatory mechanisms and is broadly relevant with direct clinical implications for the treatment of primary immunodeficiency diseases and cancer because elevated expression and increased phosphorylation of Crk are common to various cancers (e.g., lung cancer, breast cancer, glioblastoma, sarcomas, ovarian cancer, and hematopoietic cancers). The proposed work also generates a novel model system in which to determine Crk's role as a master regulatory molecule. !
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dongfang Liu其他文献

Dongfang Liu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dongfang Liu', 18)}}的其他基金

CD147-CAR-NK Cells for Hepatocellular Carcinoma Treatment
CD147-CAR-NK 细胞用于肝细胞癌治疗
  • 批准号:
    10356640
  • 财政年份:
    2022
  • 资助金额:
    $ 53.15万
  • 项目类别:
CD147-CAR-NK Cells for Hepatocellular Carcinoma Treatment
CD147-CAR-NK 细胞用于肝细胞癌治疗
  • 批准号:
    10547810
  • 财政年份:
    2022
  • 资助金额:
    $ 53.15万
  • 项目类别:
The adaptor protein Crk in immune responses
免疫反应中的接头蛋白 Crk
  • 批准号:
    10876527
  • 财政年份:
    2018
  • 资助金额:
    $ 53.15万
  • 项目类别:
The adaptor protein Crk in immune responses
免疫反应中的接头蛋白 Crk
  • 批准号:
    10326798
  • 财政年份:
    2018
  • 资助金额:
    $ 53.15万
  • 项目类别:
The adaptor protein Crk in immune responses
免疫反应中的接头蛋白 Crk
  • 批准号:
    10084254
  • 财政年份:
    2018
  • 资助金额:
    $ 53.15万
  • 项目类别:
Targeting of Master Signaling Molecule to Restore Functions of Exhausted HIV-specific CTLs
靶向主信号分子以恢复耗尽的 HIV 特异性 CTL 的功能
  • 批准号:
    9268977
  • 财政年份:
    2016
  • 资助金额:
    $ 53.15万
  • 项目类别:
HIV-1-Specific CTL Exhaustion at Immune Synapse
免疫突触处 HIV-1 特异性 CTL 耗尽
  • 批准号:
    9137404
  • 财政年份:
    2016
  • 资助金额:
    $ 53.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了